More Respimat data from Boehringer

Boehringer Ingelheim on Tuesday touted results from the Phase III CanoTinA asthma trial, which showed that adding tiotropium Respimat to maintenance asthma therapy in kids ages 6-11 significantly improves lung function compared to placebo. The results were presented Tuesday at the European Respiratory Society International Congress 2016 in London. This comes 1 day after results from another clinical trial showed the company’s drug-device Stiolto Respimat aids patients with chronic obstructive pulmonary disease walk for longer periods of time without experiencing shortness breath. The CanoTinA trial looked to investigate the use of tiotropium, a drug that helps to keep the airways to the lung open, with Respimat in kids that are already taking an inhaled corticosteroid. Respimat is not approved in the US for children under 12. “Asthma is the most common chronic childhood disease, but many children still continue to experience asthma symptoms despite taking other maintenance therapies,” Dr. Christian Vogelberg of Germany’s University Children’s Hospital Dresden said in a press release. “These new results showed significant lung function improvements for children with asthma and importantly confirm that the safety profile of tiotropium Respimat in children aged six years and above is comparable to placebo.” Study researchers found that the safety and tolerability of the drug is ...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Drug-Device Combinations Boehringer Ingelheim Pharmaceuticals Source Type: news

Related Links:

ConclusionsPatients may adapt their ICS use to their current needs without this impacting later RDAC.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Annals of the American Thoracic Society,Volume 16, Issue 10, Page 1252-1262, October 2019.
Source: Annals of the American Thoracic Society - Category: Respiratory Medicine Authors: Source Type: research
AbstractAirway inflammation is a major contributing factor in both asthma and chronic obstructive pulmonary disease (COPD) and represents an important target for treatment. Inhaled corticosteroids (ICS) as monotherapy or in combination therapy with long-acting β2-agonists or long-acting muscarinic antagonists are used extensively in the treatment of asthma and COPD. The development of ICS for their anti-inflammatory properties progressed through efforts to increase topical potency and minimise systemic potency and through advances in inhaled delivery technology. Budesonide is a potent, non-halogenated ICS that was dev...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 18 September 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Marcia Vervloet, Liset van Dijk, Peter Spreeuwenberg, David Price, Alison Chisholm, Eric Van Ganse, Hilary Pinnock, Cynthia S. Rand, Michelle N. Eakin, Tjard Schermer, Patrick C. Souverein, Alexandra L. Dima, Respiratory Effectiveness Group’s Adherence Working GroupAbstractBackgroundLow inhaled corticosteroids (ICS) adherence is associated with increased asthma burden. This relationship is likely bidirectional, and may vary across adherence stages (initiation, implementation, persistence)....
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Asthma and chronic obstructive pulmonary disease (COPD) are markedly different airway diseases, but sometimes they overlap, with some asthmatic patients showing some features of COPD (fixed airway obstruction, mixed neutrophilic/eosinophilic airway inflammation, and relatively poor response to corticosteroids) and some patients with COPD having features of asthma (atopy, history of asthma, greater airway reversibility, increased blood and sputum eosinophil counts, and a clinical response to corticosteroids).
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Editorial Source Type: research
Conclusions: The ACO cohort with statin use exhibited the lower risk of hepatic, renal, and heart failure than any other cohort, regardless of age, sex, comorbidities, or ICS or OS use. Regarding the combined use of statins and ICS, the risks of hepatic failure were lower. For the combined use of statins and OS, the hepatic, renal and heart failure were less frequent.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Abstract Vilanterol trifenatate is a novel chiral long-acting β2-agonist developed. Vilanterol combined with inhaled corticosteroids can treat COPD and asthma. A simple liquid chromatographic method is developed for the quantitative determination of R-vilanterol and S-vilanterol (impurity S). HPLC separation was achieved on Chiralpak ID (250 × 4.6 mm; particle size 5 μm) column using hexane-ethanol-ethanolamine (75:25:0.1, v/v/v) as mobile phase at a flow rate of 1.0 mL/min. The resolution is greater than 3.3. Ethanolamine in the mobile phase is vital to enhance chromatograph...
Source: Chirality - Category: Molecular Biology Authors: Tags: Chirality Source Type: research
Authors: Högman M, Thornadtsson A, Bröms K, Janson C, Lisspers K, Ställberg B, Hedenström H, Malinovschi A Abstract Exhaled nitric oxide (FENO) is a marker of type-2 inflammation in asthma and is used in its management. However, smokers and ex-smokers have lower FENO values, and the clinical use of FENO values in COPD patients is unclear. Therefore, we investigated if FENO had a relationship to different COPD characteristics in smoking and ex-smoking subjects. Patients with COPD (n = 533, 58% females) were investigated while in stable condition. Measurements of FENO50, blood cell c...
Source: COPD: Journal of Chronic Obstructive Pulmonary Disease - Category: Respiratory Medicine Tags: COPD Source Type: research
Chronic obstructive pulmonary disease (COPD) is a significant cause of morbidity and mortality worldwide, and its prevalence is increasing. Airway inflammation is a consistent feature of COPD and is implicated in the pathogenesis and progression of COPD, but anti-inflammatory therapy is not first-line treatment. The inflammation has many guises and phenotyping this heterogeneity has revealed different patterns. Neutrophil-associated COPD with activation of the inflammasome, T1 and T17 immunity is the most common phenotype with eosinophil-associated T2-mediated immunity in a minority and autoimmunity observed in more severe...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Series Source Type: research
Clinical management of asthma and chronic obstructive pulmonary disease (COPD) has primarily relied on the use of beta 2 adrenergic receptor agonists (bronchodilators) and corticosteroids, and more recently, monoclonal antibody therapies (biologics) targeting specific cytokines and their functions. Although these approaches provide relief from exacerbations, questions remain on their long-term efficacy and safety. Furthermore, current therapeutics do not address progressive airway remodeling (AR), a key pathological feature of severe obstructive lung disease. Strikingly, agonists of the bitter taste receptors (TAS2Rs) deli...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
More News: Asthma | Child Development | Children | Chronic Obstructive Pulmonary | Clinical Trials | Corticosteroid Therapy | Hospitals | Medical Devices | Politics | Respiratory Medicine | Spiriva | Study | Tiotropium